NH004

**NH004** is an investigational intra-oral dissolvable thin film formulation containing the anticholinergic agent **tropicamide** (in doses of 0.3 mg, 1 mg, or 3 mg) designed for the short-term management of **sialorrhea** (excessive drooling), a common symptom in Parkinson's disease patients that increases aspiration risk. Developed by **NeuroHealing Pharmaceuticals Inc.**, it enables localized delivery in the mouth to reduce saliva production while minimizing systemic side effects associated with traditional anticholinergics. Clinical studies, including a double-blind, placebo-controlled crossover trial (NCT00761137) sponsored with support from the Michael J. Fox Foundation, demonstrated an acceptable safety profile but did not meet primary efficacy endpoints due to high variability in baseline saliva measures, though post-hoc analyses suggested trends favoring treatment.[1][2][3][4]